PerkinElmer Inc
LSE:0KHE
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Realty Income Corp
NYSE:O
|
Real Estate
|
US |
![]() |
Walt Disney Co
NYSE:DIS
|
Media
|
US |
![]() |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
82.05
124.1313
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
3M Co
NYSE:MMM
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Realty Income Corp
NYSE:O
|
US |
![]() |
Walt Disney Co
NYSE:DIS
|
US |
![]() |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one 0KHE stock under the Base Case scenario is 1.69 USD. Compared to the current market price of 116.85 USD, PerkinElmer Inc is Overvalued by 99%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
PerkinElmer Inc
Run backtest to discover the historical profit from buying and selling 0KHE based on its intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Price Target |
Loading
|
Revenue Forecast |
|
Operating Income Forecast |
|
Earnings Forecast |
|
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
![](https://ik.imagekit.io/kkbzr2uz4cp/other/ai-assistant.png)
PerkinElmer Inc. stands as a prominent player in the field of diagnostics and life sciences, dedicated to improving human and environmental health. Founded over 80 years ago, the company has evolved to meet the demands of an ever-changing market by providing innovative solutions that span a wide range of applications, from prenatal screening to disease detection and environmental monitoring. With a strong commitment to research and development, PerkinElmer has positioned itself at the forefront of science and technology, offering cutting-edge instruments, consumables, and software that empower healthcare providers and researchers alike. The recent strategic acquisitions and partnerships have...
PerkinElmer Inc. stands as a prominent player in the field of diagnostics and life sciences, dedicated to improving human and environmental health. Founded over 80 years ago, the company has evolved to meet the demands of an ever-changing market by providing innovative solutions that span a wide range of applications, from prenatal screening to disease detection and environmental monitoring. With a strong commitment to research and development, PerkinElmer has positioned itself at the forefront of science and technology, offering cutting-edge instruments, consumables, and software that empower healthcare providers and researchers alike. The recent strategic acquisitions and partnerships have further fortified its position, allowing the company to expand its product portfolio and enhance its global footprint, making it a vital enterprise in the realms of healthcare and diagnostics.
For investors, PerkinElmer represents an intriguing opportunity marked by consistent revenue growth and a robust market presence. The company's diverse offerings not only cater to the increasing global demand for diagnostics and health technologies but also align with prevailing trends in personalized medicine and environmental sustainability. Its strong financial performance is backed by a capable management team that focuses on long-term value creation through innovation and strategic investments. As healthcare continues to evolve with advancements in technology and an ongoing emphasis on preventive medicine, PerkinElmer is well-positioned to capitalize on these trends, making it a compelling consideration for investors looking to tap into the future of health and science.
PerkinElmer Inc. operates primarily in two core business segments:
-
Diagnostics:
- This segment focuses on providing solutions for disease prevention, diagnosis, and monitoring. It includes a wide array of products and services such as in vitro diagnostics (IVD) test kits, molecular testing products, and healthcare IT solutions. The diagnostics segment supports various healthcare applications, notably in areas such as reproductive health, infectious diseases, and neonatal screening.
-
Discovery & Analytical Solutions:
- This segment offers a variety of scientific instruments, software, and services aimed at improving research and development processes across multiple industries. It serves pharmaceutical and biotechnology companies, academic institutions, and other research organizations. Key products include analytical instruments, imaging systems, and laboratory services that facilitate drug discovery and development.
These core business segments allow PerkinElmer to address a wide range of customer needs in healthcare and scientific research, driving innovations that contribute to global health improvements and advancements in analytical methodologies.
PerkinElmer Inc. holds several unique competitive advantages that set it apart from its rivals in the life sciences, diagnostics, and applied markets industries:
-
Broad Product Portfolio: PerkinElmer offers a comprehensive range of products and services, including analytical instruments, reagents, and software solutions. This diverse portfolio allows them to meet the varying needs of customers across different industries, such as healthcare, environmental testing, and food safety.
-
Strong Focus on Innovation: The company invests heavily in research and development, which enables it to remain at the forefront of technological advancements. This commitment to innovation helps PerkinElmer develop cutting-edge products that address emerging needs in areas like diagnostics and therapeutics.
-
Expertise in Niche Markets: PerkinElmer specializes in niche areas such as newborn screening and environmental health. This expertise can provide them with a competitive edge, as they have developed deep knowledge, relationships, and regulatory understanding in these specific markets.
-
Strategic Acquisitions: PerkinElmer has a history of strategic acquisitions that enhance its capabilities and market position. By acquiring companies that complement their offerings, they can expand their technological capabilities and customer base effectively.
-
Global Presence and Scalability: With operations in numerous countries, PerkinElmer has established a global footprint that allows them to serve a wide range of clients. This scale can lead to cost advantages, a robust supply chain, and improved customer service.
-
Customer-Centric Approach: The company's emphasis on building strong customer relationships and providing tailored solutions has helped it maintain loyalty and trust among its clients. By focusing on customer needs, PerkinElmer can adapt its offerings more effectively than competitors.
-
Regulatory Expertise: Given the nature of the industries they serve, PerkinElmer possesses significant expertise in navigating complex regulatory environments. This capability can streamline processes for customers and enhance the trustworthiness of their products.
-
Strong Brand Reputation: With a long history in the industry, PerkinElmer has developed a strong brand reputation for quality and reliability. This reputation can be a significant asset in attracting new customers and retaining existing ones.
-
Partnerships and Collaborations: The company often collaborates with research institutions, universities, and other organizations to drive innovation and accelerate product development, enabling them to stay ahead in technological advancements.
By leveraging these competitive advantages, PerkinElmer is well-positioned to face competition and capitalize on growth opportunities in its industry.
PerkinElmer Inc., a prominent player in the diagnostics and life sciences sectors, faces a variety of risks and challenges that could impact its business in the near future. Some of these include:
-
Regulatory Changes: Given the nature of its products and services, PerkinElmer is subject to intense regulatory scrutiny. Changes in regulations or compliance requirements, particularly related to medical devices and diagnostics, could pose challenges and affect market access.
-
Market Competition: The life sciences and diagnostics markets are highly competitive, with numerous players continually innovating. Increased competition from both established companies and new entrants could pressure pricing, market share, and profit margins.
-
Technological Advancements: Rapid advancements in technology could render existing products obsolete. PerkinElmer must continuously invest in R&D to stay competitive, which can be resource-intensive.
-
Supply Chain Disruptions: Global events, such as pandemics or geopolitical tensions, can disrupt supply chains. Any interruptions in the supply of raw materials or parts could impact production and delivery timelines.
-
Economic Downturns: Economic fluctuations can affect healthcare budgets and spending, impacting demand for PerkinElmer's products and services. Economic uncertainty could lead institutions to delay purchases or invest in lower-cost alternatives.
-
Cybersecurity Threats: Like many companies in the tech and healthcare sectors, PerkinElmer is at risk of cyberattacks. Data breaches or other cybersecurity incidents could compromise sensitive information and damage the company's reputation.
-
Dependency on Key Customers: A significant portion of revenue may come from major clients. Losing one or more of these key accounts could substantially impact revenue and profitability.
-
Talent Acquisition and Retention: The technology and healthcare sectors are characterized by intense competition for skilled labor. Attracting and retaining talent, particularly in R&D and technology roles, is crucial for innovation and maintaining competitive advantage.
-
Global Health Threats: The company’s performance is heavily influenced by public health trends. New health crises (e.g., pandemics) or failing to capitalize on emerging trends (like personalized medicine) may affect its growth prospects.
-
Currency Fluctuations: As a global company, PerkinElmer is exposed to currency exchange rate fluctuations that can impact the bottom line when translating international revenues back to the U.S. dollar.
Addressing these risks through strategic planning, diversification, and robust operational processes will be critical for PerkinElmer to navigate its challenges effectively.
Revenue & Expenses Breakdown
PerkinElmer Inc
Balance Sheet Decomposition
PerkinElmer Inc
Current Assets | 3.2B |
Cash & Short-Term Investments | 2B |
Receivables | 597.4m |
Other Current Assets | 607.1m |
Non-Current Assets | 10.3B |
PP&E | 646.9m |
Intangibles | 9.3B |
Other Non-Current Assets | 296.8m |
Current Liabilities | 1.4B |
Accounts Payable | 174.9m |
Accrued Liabilities | 503.7m |
Other Current Liabilities | 711.4m |
Non-Current Liabilities | 4.2B |
Long-Term Debt | 3.2B |
Other Non-Current Liabilities | 1B |
Earnings Waterfall
PerkinElmer Inc
Revenue
|
2.7B
USD
|
Cost of Revenue
|
-1.2B
USD
|
Gross Profit
|
1.5B
USD
|
Operating Expenses
|
-1.1B
USD
|
Operating Income
|
368m
USD
|
Other Expenses
|
-198.6m
USD
|
Net Income
|
169.4m
USD
|
Free Cash Flow Analysis
PerkinElmer Inc
USD | |
Free Cash Flow | USD |
Revvity's Q2 2024 results exceeded expectations despite facing challenges in the pharma and biotech sectors, posting a 1% organic revenue decline, which was on the higher end of projections. Margins rose significantly to 28.7%, leading to an adjusted EPS of $1.22. The company generated $160 million in free cash flow, aided by cost controls and efficiency improvements. Revvity plans to ramp up share repurchases, leveraging its strong cash position and expecting continued robust performance. The company projects a full-year adjusted EPS between $4.70 and $4.80, with expected 2024 revenue ranging from $2.77 billion to $2.79 billion.
What is Earnings Call?
0KHE Profitability Score
Profitability Due Diligence
PerkinElmer Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
PerkinElmer Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
0KHE Solvency Score
Solvency Due Diligence
PerkinElmer Inc's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Score
PerkinElmer Inc's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
0KHE Price Targets Summary
PerkinElmer Inc
According to Wall Street analysts, the average 1-year price target for 0KHE is 139.6 USD with a low forecast of 121.72 USD and a high forecast of 195.08 USD.
Shareholder Yield
Current shareholder yield for 0KHE is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
0KHE Price
PerkinElmer Inc
Average Annual Return | 16.62% |
Standard Deviation of Annual Returns | 32.69% |
Max Drawdown | -59% |
Market Capitalization | 1.3T USD |
Shares Outstanding | 11 025 900 544 |
Percentage of Shares Shorted |
N/A
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. The company is headquartered in Waltham, Massachusetts and currently employs 16,700 full-time employees. The firm operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides products and services targeted towards the life sciences and applied markets. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the reproductive health, immunodiagnostics and applied genomics markets. The firm provides early detection for genetic disorders from pregnancy to early childhood, and infectious disease testing for the diagnostics market. The company offers its products under various brand names, including AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BoBs, chemagic, Chitas, Datalytix, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROline, EUROPattern, FragilEase, Genoglyphix, GSP, and others.
Contact
IPO
Employees
Officers
The intrinsic value of one 0KHE stock under the Base Case scenario is 1.69 USD.
Compared to the current market price of 116.85 USD, PerkinElmer Inc is Overvalued by 99%.